FindTrial
Sign In

A double-blind, parallel group, comparative study of coadministration AD-4833 and SYR-322

-

Status
Unknown
Phases
Phase 4
Study type
Interventional
Source
JPRN
Registry ID
JPRN-jRCT1080221871
Enrollment
Unknown
Registered
2012-07-30
Start date
2012-07-30
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diabetes mellitus

Interventions

investigational material(s) Generic name etc : AD-4833,SYR-322 INN of investigational material : Therapeutic category code : 396 Antidiabetic agents Dosage and Administration for Investigational mate

Sponsors

TAKEDA PHARMACEUTICAL COMPANY LTD.
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Those judged to be capable of understanding and complying with protocol requirements by the investigator or subinvestigator. Those who can sign and date a written, informed consent form prior to the initiation of any study procedures.

Exclusion criteria

Exclusion criteria: Those with concurrent serious cardiac disease, serious cerebrovascular disorder, or serious pancreatic or hematological disease etc. Others who are assessed to be ineligible for the study by the investigator or subinvestigator.

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026